Anzeige
Mehr »
Dienstag, 22.09.2026 - Börsentäglich über 12.000 News
Auf diese Liste kann man sich nicht einkaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
557 Leser
Artikel bewerten:
(2)

Illumina: Does Your Dog Have Nine Lives, Too? This DNA Test Can Tell You

NORTHAMPTON, MA / ACCESSWIRE / January 6, 2023 / Originally published on Illumina News Center

In 2019, Rachel Miro was living alone in a studio apartment in Pittsburgh when she decided to foster a four-legged friend. She went to a local shelter and was immediately taken by a floppy-eared mutt with dark, expressive eyes: Milo. The shelter told that he was almost a year old.

Milo was in pretty bad shape at the time; he had parasitic worms that were affecting his health. And after Miro helped nurse him back to health, she decided to adopt him.

As a self-proclaimed "crazy dog lady," Miro was enthusiastic to learn more about her pup. "I've always been fascinated by any product promising to provide more information on my dog or enrich my dog's life," she says. She found a DNA test-one that not only traced lineage and breed specificity, but also uncovered genetic mutations associated with health risks-manufactured by a company called Embark Veterinary. The test revealed that Milo had a relative who was a few years older, and it made her want to dig deeper.

Then, in 2022, when Boston-based Embark launched a test to accurately determine a dog's age, Miro was first in line for its beta testing. Milo had just been diagnosed with arthritis, and his fur had already begun to gray. "I was puzzled as to why he'd be showing signs of aging at such a young age," Miro said. Embark's new test showed that Milo was already six and a half-far older than she'd been told. Suddenly, his arthritis, graying snout, and mature size made more sense.

Embark's vision is to use science to provide accurate answers to folks like Miro, so their dogs can live longer, healthier lives. Age and breed are the two key questions dog owners have when they adopt, says CEO and founder Ryan Boyko, and understanding a dog's genetic makeup can help their owners better feed, train, and care for them.

Embark's Dog Age Test rests on the established link between age and DNA methylation. As animals age, enzymes attach small chemical tags called methyl groups to their DNA base pairs, which regulates the expression of specific genes. Certain methylation patterns change predictably with age, meaning they can act as a sort of clock. Measuring the amount of methylation in a dog's DNA gives an accurate estimate of a dog's calendar age.

The test was developed in partnership with Illumina, as the level of DNA methylation is assessed using Illumina's Infinium Methylation Array. The canine saliva samples received from the consumer are processed using two kinds of fluorescent beads that attach to methylated and unmethylated DNA bases. The samples are scanned and a comparison of the ratio of one fluorescent signal type to the other is performed to help determine the degree of methylation. Embark analyzes the lab results and sends the consumer a report with preventive care tips.

Embark hopes this new test will be just one of many that can produce insights for pet owners. "We're looking at other technologies that build on our base of genetic and canine knowledge to help us find other ways to improve dogs' lives," Boyko says. The age test has already helped a number of dog owners, including Miro. During the company's beta testing phase, 40% of customers took action after learning their dog's true age, and about a third of those who took action sought veterinary care.

After learning Milo's true age, Miro began taking preventive measures. To limit the impact of his arthritis, she cut back on his exercise. Before, she took him on runs and hikes, but now she tracks his activity to make sure he's getting an appropriate amount without overdoing it. She also began feeding him supplements.

She's thankful that Embark's age test provided such clear answers, which should help her keep Milo happy and healthy by her side for years to come.

Learn more about how Illumina is expanding access to genomics, click here.

Illumina, Friday, January 6, 2023, Press release picture

Rachel Miro and her dog, Milo, who goes by @milomutt on Instagram.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.

Contact Info:
Spokesperson: Illumina
Website: https://www.3blmedia.com/profiles/illumina
Email: info@3blmedia.com

SOURCE: Illumina

View source version on accesswire.com:
https://www.accesswire.com/734316/Does-Your-Dog-Have-Nine-Lives-Too-This-DNA-Test-Can-Tell-You

© 2023 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.